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A Randomized Controlled Trial of Screening in the Community to Reduce Fractures in Older Women: 
The SCOOP Study 
SUMMARY 
Background 
Despite effective assessment tools and medications targeting osteoporosis and related fractures, 
screening for fracture risk is not currently advocated in the UK. We tested whether a community- 
based screening intervention could reduce fractures in older women. 
Methods 
We conducted a two-arm randomised controlled trial in women aged 70 to 85 years comparing a 
screening programme using the FRAX risk assessment tool versus usual management. The primary 
outcome was the proportion of individuals experiencing one or more osteoporosis-related fractures 
over a five-year period. In the screening arm, treatment was recommended in women identified to 
be at high risk of hip fracture, according to the FRAX 10-year hip fracture probability. This study was 
registered on the ISRCTN registry (ISRCTN 55814835). 
Findings 
12 483 eligible women, identified from primary care, participated in the trial. Of 6 233 randomised 
to screening, treatment was recommended in 898 (14·4%). Osteoporosis medication use was higher 
at the end of year one in the screening group compared to controls (15·3% vs 4·5%, respectively), 
with uptake particularly higher (78.3% at 6 months) in the screening high risk subgroup. Screening 
did not reduce the incidence of all osteoporosis-related fractures (hazard ratio: 0·94, p=0·178, 95% 
C.I. : 0·85 to 1·03), nor the overall incidence of all clinical fractures (hazard ratio: 0.94, p=0.183, 
95% C.I. : 0.86 to 1.03) but there was strong evidence for a reduction in hip fractures, a pre-
specified secondary outcome (hazard ratio : 0·72, p=0·002 95% C.I. : 0·59 to 0·89). There was no 
evidence of differences in mortality, anxiety levels or quality of life. 
Interpretation 
A systematic, community-based screening programme of fracture risk in older women in the UK is 
feasible. Whilst there was no reduction in overall fracture rate the intervention was effective in 
reducing hip fractures by an estimated 28%. 
Funding 
The Arthritis Research United Kingdom (ARUK), formerly the Arthritis Research Campaign (ARC), and 
the Medical Research Council (MRC) of the UK jointly funded this trial. 
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Introduction 
 
There are approximately 9 million osteoporotic or fragility (low trauma) fractures worldwide per 
year.1 In developed nations, around one in three women and one1 in five men aged 50 years or 
more will suffer a fragility fracture during their remaining lifetime, most commonly at sites such as 
the hip, distal forearm, vertebrae and humerus. In the UK, around 536 000 people suffer fragility 
fractures each year, including 79 000 hip fractures, with a cost in 2010 estimated at £3·5 billion 
expected to rise to £5·5 billion per year by 2025.2 For the individual, a hip fracture can be 
devastating with loss of independence and less than one third of patients making a full recovery; 
mortality at one year post-fracture is approximately 20%.3 
 
Advances in osteoporosis management over the last two decades include development of effective 
low-cost treatments and easily accessible fracture risk assessment tools, such as FRAX®. Bone 
mineral density (BMD) measurement alone has a relatively low sensitivity for fracture risk and is 
therefore of limited utility for mass screening;4,5 the FRAX tool, however, has been shown to 
increase the sensitivity for fracture risk above that provided by measuring BMD in isolation.6 
Although underpinning many guidelines internationally, no formal studies have prospectively 
examined the utility of using FRAX to target intervention and reduce fracture incidence. 
 
The aim of the SCOOP (‘screening for prevention of fractures in older women’) trial was to assess the 
effectiveness of a FRAX-based, community screening programme for UK women aged 70 to 85 years 
in reducing the incidence of fractures over a five year period. 
 
Methods 
Study Design 
The SCOOP clinical study was a pragmatic, unblinded, two group, parallel, randomised controlled 
trial to assess the effectiveness and cost-effectiveness of screening to prevent fractures in older 
women. Details of the methods have been published.7 
The primary end-point was the proportion of participants experiencing at least one osteoporosis- 
related fracture, defined in more detail below, over the five-year follow-up. Follow-up data 
collection points were at 6, 12, 24, 36, 48 and 60 months post-randomisation. 
Participants 
Participants in or around seven regions in England: Norwich, Southampton, Bristol, Birmingham, 
Manchester, York and Sheffield. Women age 70-85 years were identified through primary care lists). 
Those currently on prescription anti-osteoporotic medications (excluding vitamin D or calcium) were 
excluded (though anyone who had used such medication at any time in the past could be included); 
any individuals deemed, by their family doctor, to be unsuitable to enter a research study (e.g. 
known dementia, terminally ill, recently bereaved, etc.) were also excluded. 
Where a large number of potential participants were identified, a number were excluded, at 
random, to ensure for practical reasons that no practice had more than 500 participants. 
Written, informed consent was obtained from all participants. At this point, a self-filled 
questionnaire captured the FRAX risk factors prior to each woman being randomised to the 
intervention (screening) or control arm. Baseline data comprised age, sex, height and weight for 
Body Mass Index (BMI) calculation, and dichotomised risk variables including a prior fragility fracture 
since the age of 50 years, parental history of hip fracture, current tobacco smoking, any long-term 
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use of oral glucocorticoids, rheumatoid arthritis, other causes of secondary osteoporosis and 
daily alcohol consumption of ≥3 units daily. If the respondent did not know the answer to an 
individual question a negative response was assumed. 
Randomisation 
Allocation to study arm was conducted using blocked randomisation (block length 6), stratified 
by recruiting region and age group (70 to 74 years, 75 to 79 years and 80 to 85 years). 
Randomisation was carried out, once relevant data were obtained, using an on-line web-based 
system. This was set up by an independent data-programmer from the Norwich Clinical Trials 
Unit. A 1:1 allocation ratio was used. 
Intervention Arm 
In the screening arm, the baseline risk factor questionnaire was used to calculate the 10-year 
probability of hip and major osteoporotic fracture using the FRAX risk algorithm.8 The hip fracture 
probability was then used to decide whether or not a participant should be invited for a DXA scan 
to assess BMD.  The 10-year probability of hip fracture for each participant was compared to an 
assessment threshold for each 5-year age-band (column 1, Table 1), as determined previously in 
an analysis of treatment cost-effectiveness in the UK. 9 Each participant was classified as low or 
high risk of fracture, depending on whether their individual 10-year hip fracture probability was 
below or above the threshold probability for their age. Participants classified as low risk received 
a letter (also notified to their GP) confirming their low risk status with a recommendation that no 
further action was necessary. The remaining participants were invited to undergo a local, DXA-
based femoral neck BMD measurement and the 10-year hip fracture probability was recalculated 
with inclusion of BMD. Height and weight were measured at the DXA visit and the BMI 
information updated. The presence of rheumatoid arthritis was removed from this calculation as 
it may have been confused with osteoarthritis by participants and reliance on self-report of 
rheumatoid arthritis is not recommended for the FRAX algorithm.10 The final risk category, either 
low or high risk of fracture,(i.e. below or above the age category intervention threshold, column 
2, Table 1) was communicated to the participant and GP by letter; participants above the 
threshold were advised to make an appointment with their family doctor to discuss treatment 
options. 
Control Arm 
Apart from a letter to the GP informing them of their patient participating in the study, no 
additional information was provided and they received standard care as usual. The baseline 10-
year fracture probabilities, without the inclusion of BMD, were calculated at the end of the trial 
for comparative purposes only. 
Outcomes 
The primary outcome was the proportion of participants experiencing at least one osteoporosis- 
related fracture during the five-year follow-up period. Pre-specified secondary outcomes were 
the proportions of participants experiencing at least one hip fracture; any clinical fracture; and 
mortality. Mortality was ascertained by flagging all randomized subjects via the Office of National 
Statistics (ONS); deaths notified by family members and GPs were also confirmed by ONS data.  
The impacts on anxiety (using the short 6-item version of the State-Trait Anxiety Index (STAI)11) 
and health related quality of life (measured with EQ-5D and SF-12) were also pre-specified 
secondary endpoints.   Family doctors were asked to record any adverse events related to the 
screening process. 
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Fracture Ascertainment 
Fracture events were captured from a variety of sources. Participants self-reported any fractures 
occurring since the previous follow-up, including date and anatomical site of fracture, and hospital 
attended (if any). Routine hospital episode statistics (HES) data1, comprising information on 
hospital inpatient stays and emergency department attendance, were interrogated to identify 
fractures in any of the study participants from the point of randomisation until the end of follow-
up. Primary care records were similarly screened for fractures based upon formal Read codes. 
Where self-report or emergency department attendance were the sole source of information, or 
where there was missing information regarding exact dates or anatomical site of fracture, 
further verification included requests to primary care practices and searches of radiology records 
at local hospitals. Vertebral fractures documented within 6 months of randomisation were 
excluded due to uncertainty over the actual date of occurrence. 
Only verified fractures, at any anatomical site, within the five-year follow-up period, were 
included as outcomes. The level of trauma associated with the incident fracture was not 
recorded. Incident osteoporosis-related fractures were defined as those excluding the hands, 
feet, nose, skull or cervical vertebrae. Hip fractures were defined as verified fractures with a 
specific description of ‘neck of femur’ or ‘proximal femur’. Those described as ‘sub-
trochanteric’, ‘femoral shaft’, ‘distal femur’ or simply ‘femoral’ were not categorised as hip 
fractures. 
Statistical Analysis 
Cox’s proportional hazards model was used to estimate the hazard ratio between the two study 
arms for fractures (whether osteoporosis-related, clinical or hip fractures), together with a 95% 
confidence interval. Recruiting region, baseline FRAX risk value (without BMD, to allow use for 
control participants) and self-reported falls at baseline were included in the model. These 
variables were included as prognostic factors and agreed prior to data analysis. Death or 
withdrawal from the study were treated as censoring events. A similar approach was used to 
compare rates of mortality, with study withdrawal as a censoring event. The analysis of quality of 
life data and anxiety data used a general linear model with recruiting region, age and baseline 
value of the outcome included along with treatment arm at each time point. A repeated 
measures linear model (with repeated outcome being at the 6 follow-up time points) was also 
carried out. 
All analyses were conducted on an intention-to-treat basis with participants analysed 
according to the group to which they were randomised, irrespective of whether screening was 
completed. 
Sample Size 
The sample size was based upon the ratio of hazard for the two groups for any osteoporosis-
related fracture over the follow-up period taking into account the expected recruitment time 
and expected censored observations due to death. 12 Assumptions included a 2·5% annual 
incidence of fractures and a death rate of approximately 4·2% per annum in UK women aged 70-
85 years.13,14 Assuming a screening sensitivity of at least 65%, a treatment effect of 35% (i.e. a 
35% relative reduction in fractures in individuals on active treatment), and 80% uptake of 
treatment in the high risk group, a relative reduction in risk of fracture of 18% was estimated, 
i.e. a hazard ratio of around 0·82. This indicated a sample size of 5790 women per arm would 
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provide 90% power with 5% significance based upon the stated hazard ratio; a fracture rate of 
2·0% in the control group would reduce the power to 82%. The target sample size was thus set 
at 11580, with 5790 per arm. 
Ethical Approval and Funding 
Full ethical approval was obtained from the North Western - Haydock Research Ethics 
Committee of England in September 2007 (REC 07/H1010/70). The trial was registered on the 
International Standard Randomised Controlled Trial Register in June 2007 (ISRCTN 55814835). 
The Arthritis Research United Kingdom (ARUK), formerly the Arthritis Research Campaign (ARC), 
and the Medical Research Council (MRC) of the UK jointly funded this trial. 
 
Role of the funding bodies 
 
The funders of the study played no role in the study design, data collection, data analysis, data 
interpretation or writing of this report.  The corresponding author had full access to all data used 
in this study and had final responsibility for the decision to submit for publication. 
 
Findings 
Participants 
Participant progress through the trial is illustrated in Figure 1. A total of 52 033 women aged 70 
to 85 years were identified. Following exclusions for concurrent anti-osteoporosis medication 
use (n=6 927, 13·3%), being deemed unsuitable to enter a research study by their family doctor 
(n=3 473, 6·7%) or other exclusion reasons (n=3 033, 5·8%; e.g. ensuring no more than 500 
participants per practice), letters of invitation were sent to 38 600 women. A further 569 were 
subsequently excluded when found to be using anti-osteoporosis medication, not originally 
noted or initiated after the time of initial identification. Of the 38 031 remaining eligible women, 
11 068(29·1%) didn’t respond (despite a reminder letter) and 13 870 (36·5%) declined to take 
part. Thus, 13 029 women consented to participate, and a total of 12 495 (32·9% of those 
eligible) were randomised. The first randomisation was carried out in April 2008 and the last in 
July 2009. The last follow-up was in July 2014. The number of women randomised in each of the 
seven regions ranged from 1632 to 2055. 
Twelve participants were excluded post-randomisation: nine were on anti-osteoporotic 
medication at randomisation, two were mistakenly entered into the trial twice and one withdrew 
from the trial post-randomisation.  Thus, the results pertain to 12 483 appropriately randomised 
participants. 
Baseline Characteristics 
The screening group comprised 6 233 women with 6 250 in the control group. As expected for a 
randomised trial of this size, the two groups were closely comparable at baseline (Table 2). 
Compared to those declining participation, participants reported a better education, higher 
social- economic status, and more frequent histories of previous fracture or parental hip 
fracture. 
Screening Details 
Approximately half of those in the screening arm (3 064, 49·2%) were categorised as initial high 
risk and were invited to have a DXA scan. Of these, 247 (8·1%) did not provide a BMD result (157 
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declined the invitation, 81 unable to have hip BMD measured and nine died before scan) and 
consequently did not have an updated fracture risk calculated. Of those with BMD measured at 
the femoral neck, 898 (14·4% of the screening arm) were deemed to be at high risk after 
recalculation of their FRAX hip fracture probability (Table 2). The mean femoral neck T-score was 
-2·6 for this group. The average time from randomisation to notification of risk category in those 
invited for a DXA scan was 78 days. 
There were no serious adverse events related to screening recorded.   
Use of anti-osteoporosis medication 
By the end of the first year, 953 participants in the screening arm (15·3% of those randomised to 
the screening arm) had had at least one prescription compared with just 264 (4·5%) in the 
control arm. Exposure to treatment was higher in those categorised as high risk in the screening 
arm with 703 (78·3%) having received at least one prescription within 6 months of 
randomisation. Over the remaining years of follow-up, the proportion on treatment remained 
fairly constant in the screening arm, at around 13% to 14%, whereas there was a steady increase 
in treatment exposure in the control arm, with 833 (10·1%) receiving some prescription 
medication in the final 12 months of follow-up. During the course of the study, around 24% of 
the screening arm participants received at least one prescription for anti-osteoporosis 
medication compared with 16% of the control arm. 
 
Efficacy Outcomes 
The follow-up period provided 59 401 person-years of observation. Table 3 shows details of the 
fracture events by group. Overall, 1 975 osteoporosis-related fractures were identified in 1 657 
individuals, 13·3% of those randomised. The most common site of fracture was the distal 
forearm (614 individuals experienced 638 fractures, 338 in the control arm and 300 in the 
screening arm) followed by the hip (382 individuals experienced 392 fractures, 225 in the 
control arm and 167 in the screening arm). The estimated rate of new clinical fractures per 100 
person years were: overall 3·3, wrists 1·1, hips 0·66. 
Over 5 years, the proportion of individuals experiencing an osteoporosis-related fracture (the 
primary outcome) was similar in the screening arm compared to the control arm (12·9% v 
13·6%) with an adjusted hazard ratio (HR) of 0·94 (p=0.178, 95% C.I. : 0·85 to 1·03). A similar 
result was observed for any clinical fracture (15·3% v 16·0%, HR = 0·94, p=0·183, 95% C.I. : 0·86 
to 1·03). In contrast, in a pre-specified secondary analysis, screening led to a relative reduction 
in hip fractures of 28% compared with usual care (2·6% v 3·5%, HR = 0·72, p=0·002, 95% C.I. : 
0·59 to 0·89). 
Over 5 years, mortality rates were similar in the screening and control arms (8·8% v 
8·4% respectively, HR = 1·05, p=0·436, 95% C.I. : 0·93 to 1·19). 
There was no evidence of any impact of screening on anxiety levels (Table 4, p=0·515, 
repeated measures ANOVA). Those in the high risk group had higher levels of anxiety at 
baseline, prior to screening, but throughout the study period the mean difference between 
the high risk group and low risk group, or between the screening and control groups, were 
extremely small. We found no evidence of an impact on quality of life assessed by the EQ-5D 
or SF-12 (Tables 5 and 6). 
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Discussion 
The SCOOP study did not demonstrate an effect of screening for fracture risk on the primary 
outcome of any osteoporosis-related fracture. It did lead to a statistically and likely clinically 
significant decrease in hip fractures. As with any clinical trial, conclusions based upon 
secondary outcomes need to be treated with a degree of caution and not over-emphasised.  
To the best of our knowledge, though, this is the first time that a community-screening 
approach, based upon fracture risk, has demonstrated  any subsequent fracture reductions. 
Indeed,  in 2013, the National Screening Committee of the UK noted an absence of evidence 
supporting the introduction of screening for fracture risk in postmenopausal women;15 the 
one trial of screening identified,16 commencing in the 1990s, was deemed not to provide 
sufficiently current evidence.  An alternative recent approach that screened for prevalent 
vertebral fractures in primary care has shown promise but had treatment uptake as the 
primary outcome, rather than any decrease in fractures, and has not undergone a formal 
cost-effectiveness analysis.17  
 
The SCOOP study has demonstrated the feasibility of a community based, screening programme 
in women aged 70 to 85 years to reduce hip fractures. The overall screening process was 
relatively straightforward. Completion of the initial FRAX questionnaire was very good and the 
DXA scan attendance rate was high; few individuals decided not to, or were unable to, attend for 
a scan. There was no observed increase in average anxiety levels post-screening and an 
integrated qualitative study, conducted at the time of the trial, suggested screening was 
acceptable to both participants and primary care physicians.18 
There are a number of limitations that need to be considered. Participants represented around 
only one third of those eligible. There was evidence of a healthy selection bias; for example, the 
mortality rate over 5 years was less than half of that expected (8·6% versus an expected 19·0%, 
based upon the age distribution at entry).14 Those participating also tended be better educated 
and of a higher socio-economic status than those actively declining.  Only 14% of those screened 
were deemed at high risk, lower than the expected 20-40% of post-menopausal women 
(depending on age) according to the UK NOGG guidelines.19  Nonetheless, the rates of fracture 
observed were actually higher than  predicted prior to the study commencement. The 
discrepancy could be due to a genuine increase in fracture rates since 2001, or an under-
estimation based upon the primary care Read coding recorded in 2001, 13 or perhaps a 
combination of the two factors. 
Whilst there was no evidence that screening might reduce overall osteoporosis-related fracture 
incidence, there was strong evidence for a decrease in hip fractures. A number of reasons need 
to be considered for these results. Contamination with increased uptake of treatment in the 
control arm could have lessened the impact of the intervention; however treatment uptake in 
the first 6 months was very low (20% of that seen in the intervention arm) with a roughly linear 
increase thereafter. This suggests no significant early influence of contamination on prescribing 
in the control arm.   Treatment in the control arm may have increased over time with changes in 
standard management of osteoporosis in primary care subsequent to changes in national or 
local guidelines, hence reducing any between group differences.  This could explain the lack of 
effect regarding all OP-related fractures but would not account for the effect on hip fractures. 
The discrepancy is more likely explained by the screening method which used the 10-year risk of 
hip fracture, rather than the risk of any major osteoporotic fracture. Whilst the FRAX algorithm 
can calculate both, and the two risk values are related, they are not perfectly correlated nor 
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interchangeable. Using the hip fracture risk as the screening approach would, of course, be more 
sensitive to predicting, and therefore better at preventing, hip fractures, rather than fractures at 
other sites. This is likely to explain the discrepancy seen. 
The absolute size of decrease in hip fracture rates was 0·9%, requiring 111 individuals to be 
screened in order to avert one hip fracture. The relative risk reduction of 28%, though somewhat 
less than the 40% reduction observed in clinical trials of osteoporosis medication, is substantial 
given the absence of treatment in the greater majority of the screening group and treatment for 
a proportion of the controls. While it is possible that the reduction was due to more than just an 
effect of prescribed medication, for example the process may have influenced behaviour to 
reduce hip fractures in a selected group more open to the influence of risk information, there is 
little evidence that provision of simple health-related information can substantially reduce 
fracture risk ; studies addressing strategies to reduce fall risk, for example, have not been 
associated with significant decreases in fracture risk.20   The effect seen must also be considered 
in light of the efficacy of current treatment.  With more efficacious therapies available in future 
the rate of hip fracture reduction is likely to increase. 
Analyses of the cost of screening are currently underway and will be published in full elsewhere. 
However, preliminary findings indicate that the cost per prevented osteoporotic-related fracture 
being less than £4 500, and the cost per prevented hip fracture less than £8 000. Additionally, 
the cost per QALY gained, estimated under various scenarios, was less than £20 000.  
In conclusion, despite no overall reduction in fractures, this trial has demonstrated that 
community screening, based upon the FRAX probability of hip fracture, leads to a significant 
reduction in hip fractures in older women. Cost-effectiveness analyses are ongoing but the 
SCOOP study provides promise of an effective community-based management strategy in the 
UK, and elsewhere, to reduce hip fractures. 
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Age Group BMD Threshold Treatment Threshold1 
70-74 5.18% 5.24% 
75-79 6.81% 6.87% 
80-84 8.46% 8.52% 
85 8.39% 8.99% 
1: Post-BMD measurement 
Table 1: Risk Thresholds for invitation for BMD Measurement and Treatment. Based upon the 
FRAX 10-year probability of hip fracture. 
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Non-participants 
(N=15097)1 
Control 
(N=6250) 
Screening 
(N=6233) 
Screened High Risk 
(N= 898) 
 
 
 
Has a degree? Yes 1080 ( 9.9%) 1266 (20.3%) 1270 (20.4%) 182 (20.3%) 
Social Class3 I 570  ( 5.8%) 641 (10.3%) 615  ( 9.9%) 86  ( 9.6%) 
 II 2206 (22.4%) 1827 (29.2%) 1871 (30.0%) 266 (29.6%) 
 IIIN 1651 (16.8%) 1094 (17.5%) 1015 (16.3%) 211 (23.5%) 
 IIIM 3196 (32.5%) 1626 (26.0%) 1622 (26.0%) 163 (18.2%) 
 IV 1476 (15.0%) 718 (11.5%) 1471 (12.1%) 112 (12.5%) 
 V 739  ( 7.5%) 244  ( 3.9%) 250  ( 4.0%) 38  ( 4.2%) 
Ethnic group White 10955 (98.4%) 6160 (98.6%) 6157 (98.8%) 893 (99.4%) 
 Black 66 ( 0.6%) 26  ( 0.4%) 26  ( 0.4%) 1  ( 0.1%) 
 Asian 65 ( 0.6%) 18  ( 0.3%) 25  ( 0.4%) 3  ( 0.3%) 
 Other 47 ( 0.4%) 23   ( 0.4%) 15  ( 0.2%) 1  ( 0.1%) 
Fallen in past year? Yes 2186 (19.9%) 1700 (27.2%) 1744 (28.0%) 295 (33.0%) 
Broken bone since 50? Yes 1859 (17.0%) 1463 (23.4%) 1399 (22.4%) 409 (46.0%) 
Parents broken hip? Yes 536   ( 5.3%) 577  ( 9.2%) 585 ( 9.4%) 354 (41.6%) 
Smoker? Yes 826  ( 7.4%) 290  ( 4.6%) 290 ( 4.7%) 86 ( 9.6%) 
Alcohol units ≥3/day? Yes 383  ( 3.4%) 225  ( 3.6%) 219 ( 3.5%) 60 ( 6.7%) 
Glucocorticoid Use? Yes -- 312  ( 5.0%) 316 ( 5.1%) 113 (13.3%) 
Rheumatoid Arthritis? Yes -- 410 ( 6.6%) 426 ( 6.8%) 79 ( 9.3%) 
Secondary Causes of OP? Yes -- 1408 (22.5%) 1483 (23.8%) 267 (29.7%) 
Age (at response) Mean (SD) 76.8 (5.84) 75.5 (4.14) 75.4 (4.16) 77.2 (4.40) 
BMI Mean (SD) 26.1 (4.90) 26.7 (4.75) 26.7 (4.71) 24.4 (4.06) 
FRAX 10 year HIP 
Fracture Probability2 
Mean (SD) -- 8.5% (7.3%) 8.5% (7.4%) 17.9% (10.9%) 
FRAX 10 year Major OP 
Fracture Probability2 
Mean (SD) -- 19.3% (8.8%) 19.3% (8.9%) 30.0% (10.7%) 
 
1: Percentages are of those providing a non-missing answer. 
3: Prior to BMD results. 
3: Based on the National Readership Survey (NRS) grading : I : higher managerial or professional; II : intermediate managerial or professional; IIIN : Non-manual skilled 
workers; IIIM : Manual skilled workers; IV : Semi-skilled workers; V: unskilled or casual workers 
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Table 2 : Baseline Characteristics 
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 Control Screening  Hazard Ratio1 
(N=6250) (N=6233)  (95% C.I.) 
 
OP-Related 
    
No Fracture 5398 5428   
Fracture 852 (13.6%) 805 (12.9%)  0.94 
    (0.85 , 1.03 ) 
    p=0.178 
Hips     
No Fracture 6032 6069   
Fracture 218  ( 3.5%) 164  ( 2.6%)  0.72 
    (0.59 , 0.89 ) 
    p=0.002 
All Clinical     
No Fracture 5248 5282 
Fracture 1002 (16.0%) 951 (15.3%)  0.94 
 (0.86 , 1.03 ) 
p=0.183 
Mortality 
Survive 5725 5683 
Died 525 ( 8.4%) 550 ( 8.8%)  1.05 
 (0.93 , 1.19 ) 
p=0.436 
1: Adjusted for Recruiting Region, Baseline FRAX Probability and Falls. 
Table 3 : Efficacy Outcomes.  All clinical fractures included all osteoporosis (OP)-related fractures as 
well as fractures of the hands, feet, ankle, face and skull. 
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 Low Risk 
(N=5088) 
High Risk 
(N= 898) 
Control 
(N=6250) 
Estimated 
Difference1 
p-value2 
 
Baseline 
 
10.1 (3.65) 
 
10.5 (3.73) 
 
10.2 (3.68) 
 
- 
 
- 
6 Months 10.2 (3.78) 10.2 (3.74) 10.2 (3.67) 0.045 0.961 
12 Months 10.2 (3.71) 10.3 (3.91) 10.2 (3.70) -0.085 0.809 
24 Months 10.2 (3.71) 10.4 (3.76) 10.2 (3.76) -0.154 0.562 
36 Months 10.3 (3.73) 10.5 (3.87) 10.3 (3.73) -0.081 0.756 
48 Months 10.4 (3.78) 10.4 (3.68) 10.4 (3.75) -0.093 0.647 
60 Months 10.5 (3.83) 10.6 (3.70) 10.4 (3.81) -0.184 0.226 
   Repeated Group3 0.515 
   Measures Group*Time4 0.942 
   Analysis   
 
1: Control – High Risk, adjusted for Recruiting Region, Age and Baseline STAI. 
2: Test of any group difference 
3: Repeated Measures ANOVA test of between group difference 
4: Repeated Measures ANOVA test of group by time interaction 
Table 4 : State-Trait Anxiety Inventory (Short Form) over five years follow-up, Mean (SD). This scale 
ranges from 6 to 24, with lower scores indicating lower levels of anxiety. 
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 Intervention 
(N=6233) 
Control 
(N=6251) 
Estimated 
Difference1 
p-value2 
 
Baseline 
 
0.74 (0.24) 
 
0.74 (0.23) 
 
- 
 
- 
6 Months 0.74 (0.24) 0.74 (0.24) -0.003 0.394 
12 Months 0.74 (0.25) 0.73 (0.25) -0.010 0.020 
24 Months 0.71 (0.27) 0.72 (0.26) -0.003 0.537 
36 Months 0.68 (0.29) 0.69 (0.28) -0.006 0.273 
48 Months 0.67 (0.31) 0.66 (0.30) -0.008 0.154 
60 Months 0.63 (0.33) 0.63 (0.32) -0.003 0.642 
  Repeated Group3 0.154 
  Measures Group*Time4 0.586 
  Analysis   
 
1: Control – Intervention, adjusted for Centre, Age and Baseline EQ-5D 
2: Test of group difference 
3: Repeated Measures ANOVA test of between group difference 
4: Repeated Measures ANOVA test of group by time interaction 
Table 5 : EQ-5D over five years follow-up (Deaths imputed to zero). 
19 
 
 
 Intervention 
(N=6233) 
Control 
(N=6250) 
Estimated 
Difference1 
p-value2 
 
Baseline 
 
45.0 (10.5) 
 
45.3 (10.2) 
 
- 
 
- 
6 Months 44.8 (10.8) 44.8 (10.7) -0.26 0.087 
12 Months 44.5 (11.3) 44.6 (11.3) -0.23 0.182 
24 Months 43.0 (12.7) 43.3 (12.4) -0.06 0.753 
36 Months 41.6 (14.1) 41.7 (13.9) -0.22 0.349 
48 Months 40.1 (15.5) 40.1 (15.3) -0.26 0.317 
60 Months 38.3 (16.7) 38.3 (16.6) -0.20 0.481 
  Repeated Group3 0.237 
  Measures Group*Time4 0.881 
  Analysis   
 
1: Control – Intervention, adjusted for Centre, Age and Baseline SF-12. 
2: Test of group difference 
3: Repeated Measures ANOVA test of between group difference 
4: Repeated Measures ANOVA test of group by time interaction 
Table 6(a): SF-12(Physical Health) over five years follow-up (Deaths imputed to zero). 
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 Intervention 
(N=6233) 
Control 
(N=6250) 
Estimated 
Difference1 
p-value2 
 
Baseline 
 
53.1 ( 8.5) 
 
53.1 ( 8.5) 
 
- 
 
- 
6 Months 52.4 ( 9.5) 52.2 ( 9.5) -0.24 0.164 
12 Months 51.8 (10.3) 51.6 (10.3) -0.17 0.382 
24 Months 50.8 (12.3) 51.1 (11.9) 0.29 0.210 
36 Months 49.4 (14.3) 49.6 (14.3) 0.07 0.805 
48 Months 47.9 (16.4) 47.9 (16.3) 0.19 0.535 
60 Months 46.0 (18.3) 46.3 (18.2) 0.56 0.103 
  Repeated Group3 0.554 
  Measures Group*Time4 0.056 
  Analysis   
 
1: Control – Intervention, adjusted for Centre, Age and Baseline SF-12. 
2: Test of group difference 
3: Repeated Measures ANOVA test of between group difference 
4: Repeated Measures ANOVA test of group by time interaction 
Table 6(b): SF-12(Mental Health) over five years follow-up (Deaths imputed to zero). 
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Summary 
 
Osteoporotic, or low-trauma, fractures – in particular hip fractures – present a considerable 
burden to the National Health Service and, to the individual, have major adverse effects on 
quality of life in terms of pain and disability. Around 50% of hip fracture patients lose the 
ability to live independently and 20% die within a year of their fracture; one-quarter of the 
excess is attributable to the fracture itself, rather than pre-existing co-morbidity. 
 
Given the availability of treatments of demonstrated efficacy and a potential screening tool 
based upon clinical risk factors and bone mineral density (the WHO risk algorithm), a prima 
facie case exists to undertake a community-based controlled evaluation of screening for 
subjects at high risk of osteoporotic fractures. 
 
This study, following on from an 18 month feasibility study, is a UK 7 centre, unblinded, 
pragmatic, randomised controlled trial lasting 87 months with a minimum of 5 years follow- 
up. A total of 11 580 women, aged 70 to 85 and not currently on prescription medication to 
prevent osteoporotic fractures, will be consented to the trial by post via primary care. This 
will provide 90% power to detect an 18% decrease in fractures. 
 
Upon receipt of valid baseline data, participants will be randomised to either a screening arm 
or control arm. Those in the screening arm will have a 10-year fracture probability computed 
from baseline risk factors together with bone mineral density measured via a DXA scan in 
selected subjects. Individuals above an age-dependent threshold will be recommended for 
treatment (typically an oral bisphosphonate) to continue treatment for the duration of the 
trial. The risk of fracture will not be calculated for subjects in the control arm, who will receive 
“usual care”. 
 
Study subjects will be followed-up at 6 months after randomisation and annually by postal 
questionnaires and checking of hospital radiology and admissions records plus primary care 
sources. The primary outcome measure will be the proportion of individuals sustaining 
fractures in each group; hip fracture rate will be a secondary outcome measure. An economic 
analysis will be carried out to assess cost-effectiveness. A qualitative evaluation will also be 
conducted to examine the acceptability of the DXA scanning and risk assessment process to 
participants. 
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1. Study Identifiers 
 
1.1 Full title of trial 
 
A pragmatic randomised controlled trial of the effectiveness and cost effectiveness of 
screening for osteoporosis in older women for the prevention of fractures. 
 
1.2 Acronym (only if applicable - this is not a requirement) 
‘SCOOP’ – Screening Of Older women for Prevention of fracture 
 
1.3 ISRCTN 
55814835               
2. Study Background 
2.1 The problem to be addressed 
 
Osteoporosis is defined as a systemic skeletal disease characterised by compromised bone 
density and quality, predisposing to an increased risk of fracture [1]. Definitive clinical 
diagnosis requires measurement of bone mineral density (BMD). The current reference 
diagnostic standard is dual-energy x-ray absorptiometry (DXA) of the femoral neck 
[2].Osteoporosis is conventionally diagnosed when BMD values lie 2.5 standard deviations or 
more below the young adult reference age, a T-score less than -2.5 SD. Studies suggest that 
about 20% of all western women over the age of 50 years have osteoporosis and that the 
prevalence increases exponentially with age [3]. 
 
The clinical significance of osteoporosis rests with the increased fracture risk and the 
consequent increased morbidity and mortality. Within Europe, osteoporotic fractures  account 
for almost 2% of the burden of non-communicable disease and are associated with more 
disability adjusted life-years (DALYs) than common cancers, with the exception of  lung 
cancer. The DALYs lost in Europe due to osteoporosis (2.0 million) are greater than for 
rheumatoid arthritis (1.0 million) [4]. Osteoporosis increases the risk of bone fracture at all 
sites, but typical ‘low-trauma’ fractures occur at the distal forearm, the vertebrae and the 
hip. It has been estimated that nearly one woman in two will experience an osteoporosis 
related fracture following menopause [5]. More than 200 000 fractures occur in the UK each 
year as a direct result of osteoporosis [6]. These fractures have major adverse effects on 
quality of life in terms of pain and disability and around 50% of hip fracture patients lose the 
ability to live independently [7]. Furthermore 20% die within a year of their fracture [8]; one-
quarter of the excess is attributable to the fracture itself, rather than pre-existing co-
morbidity. The average stay in hospital is 27 days and hip fractures account for more than 
20% of all orthopaedic bed occupancy. Each year the estimated 70,000 hip fractures in the 
UK cost health and social services £1.7 billion [9]. With an aging population, the cost to 
society and individuals of treatment, rehabilitation and premature mortality is set to increase. 
 
Interventions to reduce fracture risk 
There is compelling evidence that pharmacological interventions, such as hormone 
replacement therapy (HRT), vitamin D and calcium, strontium ranelate or bisphosphonates, 
can significantly decrease the incidence of osteoporotic fractures [10] [11] [12] [13] [14] 
[15]. Studies of bisphosphonates in osteoporotic women suggest an estimated reduction in 
vertebral fracture risk of around 50% [14], [15], a reduction in non-vertebral fractures of 20-
30% and a global risk reduction of approximately 35% for all fractures. 
 
At or around the menopause, however, there are uncertainties concerning the ultimate impact 
of, say, 5-10 years of intervention on fracture risk in later life. Most epidemiological 
information indicates that, whereas the risk of fracture is reduced in women taking HRT, for 
example, the effect appears to wane over a period of 15-20 years. Thus, interventions offered 
around the time of the menopause are likely to have little or no effect at the age of, 
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say, 70 years when the risk of fracture begins to increase most sharply. There is increasing 
evidence that the impact of treatment would be greater if started at a later age. In a Health 
Technology Assessment review of the treatment of established osteoporosis, where 
intervention thresholds were based on a cost utility cut-point of £20,000/QALY, several 
treatments including calcium, HRT and bisphosphonates were found to be cost-effective when 
used in individuals with osteoporosis aged 70 years or older [16]. Further, if one assumes 
that 25% of women in this age group have a relative risk of 2 or greater and that treatment 
is 50% effective, then fracture incidence could be decreased by between 23%  and 26% [16]. 
It is reasonable therefore to propose that the identification of fracture risk in older women 
followed by appropriate treatment of proven effectiveness could substantially reduce fracture 
incidence. 
 
Screening strategies 
The role of BMD as a predictor of future fracture risk is well established. Many cross- sectional 
and prospective studies demonstrate a 1.5-2.5 fold increased risk of fracture for every 
standard deviation decrease in BMD [17]. The predictive ability of BMD for future hip fracture 
is comparable to that of blood pressure measurement for stroke and better than that of serum 
cholesterol measurements for cardiovascular disease. 
 
However, BMD measures show poor sensitivity for future fracture. Even assuming a 2-fold 
increase in risk for each standard deviation decrease in BMD, the sensitivity remains below 
50% over most reasonable assumptions, i.e. over half of those who suffer fractures would 
not be identified as at risk. Recent empirical evidence has demonstrated the low sensitivity 
of BMD alone in the prediction of fractures. In a Rotterdam based study [18] only 44% of 
women suffering a non-vertebral fracture over an average follow-up of 6.8 years had a T- 
score of less than -2.5 SD; over 12% had normal BMD levels. A study from the US [19] found 
only 46% of women suffering a hip fracture over a 5 year period had T-scores less than -2.5 
SD at baseline. Thus, if treatment is based solely upon BMD many women at high risk that 
would benefit from treatment, perhaps the majority based upon a T-score  threshold of -2.5, 
would not be identified as such. Based upon its low sensitivity and also  for reasons of cost 
and accessibility, the Royal College of Physicians’ (RCP) guidelines on the prevention and 
treatment of osteoporosis, produced in 1999, recommended that DXA measurements be used 
in a case-finding strategy rather than used for general  screening [6]. 
 
The relatively low sensitivity partly reflects the multi-factorial causality of fractures and the 
influences of BMD-independent risk factors both within and external to the skeleton. The WHO 
Collaborating Group at Sheffield is coordinating a meta-analysis of independent risk factors 
for fracture from 8 prospective international cohorts including a recent Sheffield cohort. In 
this analysis of approximately 45,000 men and women, the following risk factors have been 
investigated: age, prior fragility fracture, low BMI, prior corticosteroid exposure, a family 
history of fragility fracture, secondary causes of osteoporosis (e.g. rheumatoid arthritis), very 
low calcium intake, smoking and alcohol [20]. It is important to note that this strategy has 
not incorporated risk factors such as stroke or falls that may not be amenable to the 
interventions to be used in this study. The combination of clinical risk factors with BMD 
provides a more accurate assessment of risk than is possible with BMD alone and therefore 
substantially increase the sensitivity (up to approximately 70% depending on the gradient of 
risk and the proportion of the population deemed to be at high risk) without significantly 
impairing specificity [16]. More women would be appropriately treated and the potential to 
reduce fracture rates improved. 
 
The validity of clinical scoring systems in predicting future fracture risk has been 
demonstrated [21] [22] [23] and the collaborating centre at Sheffield has validated the utility 
of integrating risk factors in independent cohorts with more than 1 million patient years of 
observation [24]. A strong case can be made, therefore, for evaluating a screening strategy 
which combines a self-completed risk assessment questionnaire followed subsequently by 
DXA to refine risk estimation where necessary. A further major attraction of an initial self-
completed clinical risk factor approach is its ease and low cost of application and hence the 
likely high uptake rate. DXA BMD measurement would, in such a strategy, only be used in a 
targeted fashion thus reducing costs. 
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By incorporating the hazard of fracture with the hazard of death over a ten year period an 
absolute 10-year probability of fracture can be estimated [25] [26], providing a simple metric 
against which intervention thresholds can be established. The use of an absolute risk rather 
than a relative risk for establishing intervention thresholds has been argued for on the basis 
of numerous advantages [27]. Similar approaches have been used in the management of 
cardiovascular diseases where smoking, blood pressure, diabetes  and serum cholesterol are 
used to identify patients at high risk. 
 
A possible counterargument to the evaluation of risk in the absence of BMD measures is that 
studies of efficacy have largely been undertaken in individuals with known low BMD. 
Treatment may not, therefore, be as effective when prescribed on the basis of a non-BMD 
risk assessment. For example, the efficacy of risedronate could not be demonstrated in 
women over the age of 80 selected primarily on their risk of falling [14]. However, many 
clinical risk factors also influence BMD and can identify sub-populations with low BMD [26]. 
Furthermore, empirical data from several studies demonstrate that anti-resorptive therapy 
achieves similar relative risk reduction across a range of BMDs including raloxifene, [28] 
risedronate [29], alendronate [30] and strontium ranelate [12]. 
 
2.3 The need for a trial 
 
The prevalence of, and awareness of, osteoporosis is increasing. Given the magnitude of the 
public health problem posed by osteoporotic fractures – in particular hip fractures – and the 
existence of acceptable screening modalities and acceptable treatments of demonstrated 
efficacy (in terms both of slowing or reversing decline in bone density and in terms of reducing 
fracture rates), a prima facie case now exists to undertake a formal but realistic community-
based controlled evaluation of screening for subjects at high risk of osteoporotic fractures. 
There is a large information gap in this area; there has never been, for example, any formal 
assessment of the RCP guidance published in 1999. 
 
Although many of the Wilson and Jungner [31] criteria for screening may already be judged 
to be met, the overall cost effectiveness of a screening program will be determined by the 
ease and acceptability of the screening “test” (and hence the uptake rate), alongside the 
ability of the assessment to predict fracture risk, the effectiveness of treatment and the cost 
of the program. 
 
Given the proposed screening modality (initial clinical risk approach augmented selectively 
by BMD measurement), treatments of newly demonstrated efficacy, and the target age group 
(older rather than peri-menopausal) together with some evidence from empirical studies (see 
below) it would appear timely to propose a large scale controlled empirical examination of 
the potential effectiveness of an offer of screening to the older female population. An 
adequately powered randomised controlled trial is of critical importance to determine whether 
the predicted benefits of screening and treatment are observed in a general setting. 
 
Further, the guidelines published by the National Institute for Clinical Excellence in January 
2005 [32] on secondary prevention of fragility fractures in postmenopausal women stated 
the need to consider the identification of women at risk using risk factors other than age  and 
BMD. 
 
An 18 month feasibility study commenced in April 2005 in Norwich and Sheffield, and has 
now been completed. This was funded by a £200 000 grant from the Arthritis Research 
Campaign (arc). Over 500 subjects were recruited into the study from 15 different primary 
care practices. The resulting data have informed the design of the main trial, particularly 
providing accurate data for a sample size calculation and costs and demonstrating the 
logistical feasibility. 
 
No systematic review has been published of screening for osteoporosis but a systematic 
review of the literature has been carried out. In the US, where screening for osteoporosis in 
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women over the age of 65 has become standard practice, just one clinical trial of screening 
has been published [33]. This was not, however, a trial of screening versus non-screening 
but a trial of 3 different screening strategies. In the UK, just two clinical studies of screening 
for osteoporosis have been identified. The first, carried out in Aberdeen in 1993 examined 
concordance with HRT use in peri-menopausal women after a DXA scan [34]. The second, 
the only randomised controlled trial of screening for osteoporosis identified, also carried out 
in Aberdeen, considered women aged 70 years and older [35]. This study used a simple 
clinical tool completed by study subjects at their GP surgery combined with ultra-sound 
measurements. Those considered at high risk were prescribed calcium and vitamin D 
supplements and given advice on falls prevention. The primary endpoint was the number of 
falls experienced over a three year follow-up and fractures sustained was a secondary 
endpoint. This study demonstrated the applicability of screening in this population, in terms 
of subjects’ participation. There was a decreased number of falls in the screening group and 
a 50% decrease in fractures. However, this trial did not use BMD measures, fracture was not 
the primary outcome measure and no economic analysis was performed. 
 
2.3 Principal research questions 
 
The primary research question is whether a community based screening program for 
osteoporosis reduces the incidence of fractures, and is cost-effective, in older women. 
Secondarily, the study will assess, using a qualitative approach, the acceptability of the 
screening process to participants. 
 
The results from the trial will make a critical and timely contribution to the evidence-base 
regarding the introduction of a nationally organised screening program. 
 
2.4 Study risks 
 
The trial does not involve new medicinal products or any invasive or potentially harmful 
procedures and is considered low risk for participants. 
 
The only risks directly related to the screening process come from the exposure to radiation 
from the DXA scan and the psychological impact of being declared at high risk of fracture 
from the screening process. The former is negligible. A DXA scan of the femoral neck is no 
more than 0.02 mSv, equivalent to 3 days background radiation, and substantially less than 
a standard hip x-ray (0.7 mSv). One study [36] considered the psychological impact of being 
at high risk of osteoporotic fracture, based upon a low BMD score. This study concluded that 
general anxiety in women with a low BMD score 3 months after the scan was similar to that 
2 weeks prior. Those without a low BMD score had lowered anxiety (about half a standard 
deviation) in comparison. Another study, using qualitative methods, however, suggested that 
women informed of a higher risk were left feeling more uncertain and restricted than 
previously [37]. It is intended, therefore, to consider stress and anxiety caused by screening 
as a formal part of the proposed clinical trial using both self report quantitative and qualitative 
data. 
 
As with any screening program there may be the risk of anxiety over a 'positive' result but 
all participants deemed at risk of fracture will be notified to their GP who will be able to discuss 
therapeutic intervention options. 
 
The main risk to the trial comes with the possibility of low recruitment. However, there is a 
degree of flexibility in the recruitment procedure to allow for shortfalls at early stages to be 
made up later. Also, the feasibility study that has been run has provided sound evidence upon 
which recruitment rates have been based. 
 
Ascertainment of the primary outcome measure does not rely wholly on the actions of study 
participants (fractures can still be ascertained despite non-response), and therefore follow- 
up data should be very good. 
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3. Trial Design 
 
 
3.1 Trial Outline 
 
The study has been designed as a multi-centre, unblinded, pragmatic, randomised controlled 
trial lasting 87 months, comprising a 9 month ‘pre-trial’ period, 16 month recruitment and 
screening period, 60 month treatment/follow-up period (over-lapping with the recruitment 
and screening) and a final 6 month analysis and dissemination period. The key phases of the 
trial are shown in Figure 1. 
 
A total of 11 580 women aged 70 to 85, recruited for reasons of generalisability and capacity 
from seven separate geographical areas within England, will be consented to the trial by post 
and asked to complete a baseline questionnaire including demographic and clinical variables. 
 
Upon receipt of valid baseline data, participants will be randomised to either a screening arm 
or control arm. Those in the screening arm will have a 10-year fracture risk computed from 
the baseline information followed by bone mineral density measured via a DXA scan in 
selected subjects. If an individual’s risk lies above an agreed, age-dependent threshold the 
subject’s GP will be recommended to consider introducing treatment (treatment 
recommendations based on current best evidence will be offered, currently an oral 
bisphosphonate) and continuing treatment for the duration of the trial. The risk of fracture 
will not be calculated for subjects in the control arm who will receive “usual care”. 
 
All trial subjects will be followed-up at 6 months post-randomisation and then annually by 
postal questionnaires, plus checking of hospital radiology and admissions records and primary 
care sources. The primary outcome measure will be the proportion of individuals sustaining 
fractures in each group; hip fracture rate will be a secondary outcome measure. An economic 
analysis will be carried out to assess cost-effectiveness. 
 
A qualitative evaluation will be conducted to examine the acceptability of the DXA scanning 
and risk assessment process to participants. 
 
3.2 Trial interventions 
 
Subjects in the intervention screening arm of the trial will have a ten year risk of fracture 
calculated from a WHO risk algorithm. This is based upon questionnaire data and, for some 
subjects, results from a DXA scan [26]. The WHO algorithm is calibrated to the epidemiology 
of the country, and the impact of risk factors on mortality is also incorporated. Based on this 
information, a recommendation to consider treatment or not will be communicated to 
subjects’ GPs. 
 
The fracture probability will be calculated from the reported individual details. These comprise 
age, sex, weight (in kg) and height (in cm). Body Mass Index (BMI) is automatically computed 
from height and weight (kg/m2). Dichotomised risk variables are: a prior fragility fracture, 
parental history of hip fracture, current tobacco smoking, ever long- term use of 
corticosteroids, rheumatoid arthritis, other causes of secondary osteoporosis  and daily 
alcohol consumption of ≥3 units daily. If responses are missing, subjects will be contacted to 
obtain the required information. If the subject does not know the answer to an individual 
fracture risk question, a negative response will be assumed. 
A 10-year probability of hip, clinical spine, shoulder or wrist fracture and also a 10-year 
probability of hip fracture alone are then calculated based upon this information. This former 
probability is then compared to an intervention threshold for each 5-year age-band (see table 
1) at which treatment is cost-effective based on data from within the UK [38]. Subjects with 
a low probability relative to the threshold, and their GPs, will receive a letter confirming their 
low risk status and no further action will be taken. The remaining subjects will be invited to 
undergo a BMD assessment (using DXA) and the fracture probability 
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recalculated following inclusion of the femoral neck BMD (as a T-score). Following this, the 
final category (below or above treatment threshold) will be communicated to the subject and 
GP by letter. Those subjects above the treatment threshold will be asked to make an 
appointment with their GP (or appropriate health care professional in the practice) to  discuss 
treatment options. 
 
Table 1: Risk Thresholds for BMD Measurements and Treatment 
 
Age Group BMD Threshold Treatment Threshold 
70-74 5.18% >5.24% 
75-79 6.81% >6.87% 
80-84 8.46% >8.52% 
85 8.39% >8.99% 
 
At 3 months after this letter has been sent, study subjects above the treatment threshold will 
be contacted by phone and asked whether or not they have yet seen their GP. If they have 
not, they will be encouraged to visit their GP in order to discuss treatment options. A follow-
up letter will also be sent. Those subjects that have already seen their GP will be asked if 
they have been prescribed treatment and whether or not they are taking that treatment. If a 
negative response is given, the benefits of taking the treatment will be described and the 
study subject will be encouraged to speak to their GP again if they are experiencing any 
difficulties with treatment.  A follow-up letter will again be provided. 
 
There are likely to be women in the intervention group who will not be concordant with 
screening (although data from the pilot study suggests that this number is very small – only 
1 person of 66 in Norwich failed to keep a DXA appointment) or non-adherent with treatment 
if deemed necessary. However, this is part of the pragmatic nature of the study and the 
effectiveness of a screening program, which is being estimated, would be  dependent upon 
concordance. Treatment adherence will be investigated at follow-up as a process measure. 
 
The control group will have the same initial  risk data collected by questionnaire but their risk 
will not be calculated nor communicated to their GP until the study is completed and used 
only to consider baseline comparability. Both experimental and control groups will be provided 
with lifestyle advice through an arc booklet on osteoporosis. 
 
3.3 Duration of treatment period 
 
The screening process involves up to two stages (baseline questionnaire and DXA) with up to 
one reminder/further appointment sent for each stage. This process will be completed within 
6 months of randomisation. The screening process will take place only once during the trial. 
The recommended treatment duration for women found to be above the fracture risk 
threshold will be the duration of the follow-up period, i.e. 5 years. Termination of treatment 
at the end of the study will be at the GP’s discretion. 
 
3.4 Study Subject Selection 
 
Study subjects will be selected from the general community after identification via primary 
care. The following entry criteria will be used : 
 
Inclusion : 
• Female 
• Aged 70 to 85 years inclusive 
• Providing informed consent and necessary baseline information. 
Exclusion : 
• Known to be on prescription treatment for osteoporosis (other than calcium and 
vitamin D) 
• Any known co-morbidity that would in the GP’s opinion make entry to the trial 
inadvisable (for example advanced malignancy) 
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• Other factors that would make invitation to participate to a research study 
inappropriate (e.g. recent bereavement). 
 
3.5 Sample size calculations 
 
The sample size is based upon the ratio of hazard for any fracture over the follow-up period 
of 5 years between the two groups, taking into account the recruitment period and expected 
drop outs due to death [39]. 
 
Within this age group, an epidemiological study [40] of fracture rates in England and Wales 
indicates an incidence of between 2.0% and 2.5% per annum. National statistics suggest a 
death rate of approximately 4.2% per annum in females in this age group. Assuming a 
treatment effect of 35%, a sensitivity of at least 65% and 80% uptake of recommended 
treatment, a realistic relative reduction in risk of fracture would be around 18%, i.e. a hazard 
ratio of 0.82. Assuming a fracture rate of 2.5% per annum in the control arm these data 
indicate a sample size of 5790 women per arm would provide 90% power with 5% significance 
based upon the stated hazard ratio; a fracture rate of 2.0% in the control group would reduce 
the power to 82% for the same sample size. 
 
The recently run pilot study in Norwich and Sheffield suggested a participation rate of around 
24% in those eligible for study entry. This participation rate is likely to be lower  than that of 
a full scale study as publicity was limited and no reminder letters were sent. However, based 
on this rate, an estimated 50 350 women will need to be invited to join the study in order to 
achieve a total sample size of 11 580 for randomisation. 
 
3.6 Recruitment 
 
Recruitment will take place through primary care. Primary care practices will be recruited to 
the study after supplying written information and a visit by one of the local research team to 
explain the study and what participation would entail. 
 
Subjects meeting the inclusion criteria of being female and aged between 70 and 85 years 
will be identified by participating GP practices (or by PCT information support services on their 
behalf). GPs will then be asked to screen out those meeting the exclusion criteria and letters 
of invitation, signed by GPs, with information leaflets will be mailed to those remaining. 
Identifiable details will remain within the NHS until written consent has been obtained from 
participants. There will be an option to decline to participate but to return some demographic 
and fracture history data, plus a reason for declining, in  order to compare with participating 
subjects. Further, at this stage, potential subjects will be informed of the possibility of being 
approached to take part in other related studies (e.g.  the qualitative studies outlined below). 
Those agreeing to participate in the SCOOP trial will be asked to indicate (by ticking a box on 
the consent form) if they would prefer not to be approached about these additional studies. 
 
Reminder letters will be sent after 18 days if no response is initially received. Those willing to 
participate and returning valid consent forms will be sent baseline questionnaires (see 
4.1 for details) and on receipt of these will be entered into the study and randomly allocated 
to either intervention or control. 
 
Three rounds of invitation, each with a duration of approximately 8 months from invitation to 
treatment decision and staggered by 4 months, will be carried out to decrease the intensity 
of work load in each centre (i.e. recruitment will be spread over a 16 month period). This 
approach will also allow flexibility in the number of invitations sent out in the second and third 
phases, depending on earlier take up. Based upon data from the pilot study it is anticipated 
that a total of 50 350 invitations will be required to achieve the necessary sample size. The 
main phases of recruitment from invitation through to the first follow-up visit are shown in 
Figure 2. 
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3.7 Randomisation 
 
Block randomisation (length 6) stratified by age group (70 to 74 years, 75 to 79 years and 
80 to 85 years) and general practice. The incidence of fracture is strongly age related making 
age stratification sensible. Randomisation will be carried out once relevant data is entered 
into the database based upon a random number generator. This system was successfully 
used at both centres in the feasibility study. 
 
3.8 Blinding 
 
Blinding of the study participants is clearly not feasible, nor is it feasible to blind all members 
of the project team actively involved in the execution of the study. The primary endpoint is 
objective however and very unlikely to be influenced by study subjects’ knowledge of group 
membership. To safeguard against the small residual risk of biased ascertainment of 
fractures, those research staff responsible for interrogating hospital systems to ascertain 
fracture outcome will be blinded to group allocation. In addition the member of the study 
team responsible for outcome analysis will be kept blind to group allocation. The study will 
therefore have the defining attributes of a single blind study. 
Contamination between study arms is another potential problem. Knowing that a subject is 
participating in the trial, irrespective of study group, may prompt a GP to consider the 
subject’s risk for osteoporosis more carefully than would otherwise have been the case. A 
possible approach to counter this would be through the use of a cluster randomised design, 
i.e. randomisation by practice rather than individuals. However, the approach requires a 
substantially larger sample size. Calculations based upon the recent Sheffield MRC study 
indicate that around a 3-fold increase in sample size would be required. In addition arguments 
have been proffered that a cluster randomised approach is often not an efficient means of 
avoiding contamination [41]. In order to reduce the possibility of contamination, GPs will not 
be told the weighting given to the clinical risk factors used to calculate the ten- year risk 
score, nor will they be shown copies of the risk scoring system. 
 
3.9 Follow-Up 
 
Follow-up will be for a minimum of 5 years post-randomisation (longer for those subjects in 
the earlier phases of recruitment). However, should further funding be available by the 
termination of the trial, it is anticipated that those subjects remaining in the study will be 
contacted to request consent for further follow-up as an epidemiological cohort. 
 
3.10 Loss to Follow-Up 
 
The most likely loss to follow-up will be due to death which will be around 4.2% per annum. 
This loss has been explicitly included in the sample size calculation above. It is unlikely that 
there will be substantial loss to follow-up from migration as this age group tends to be 
geographically stable. 
 
Any individuals that are lost to follow-up will be included in the main analysis with time to 
fracture if this is known to be the case or censored at loss-to-follow-up time otherwise. 
 
4. Data Collection and Analysis 
Data collection will occur at invitation, baseline (prior to randomisation), at 6 months post- 
randomisation, 12 months post-randomisation and annually thereafter for a  follow-up period 
of 5 years. A schedule of data collection is shown in Figure 3 and documentation in Figure 4. 
The array of outcome measures will be deliberately parsimonious, focusing on the outcomes 
of key interest only and optimizing response rates. 
 
Study participants will be sent questionnaires by post at follow-up to gather self-report 
fracture data, quality of life and psychological anxiety data, and medication adherence data 
as detailed below. Closed response data on the quality of life and psychological anxiety 
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questionnaires will not be monitored routinely. However, if a participant includes written 
comments on a questionnaire (or other correspondence) that raise serious concerns about 
her health (particularly when those comments appear to be directed at the GP or other 
healthcare provider) the local PI or study co-ordinator will contact the participant to discuss 
the comments and ask whether she wishes the study centre to contact her GP on her behalf 
regarding the issue. On rare occasions, it may be necessary for the study centre to refer 
serious concerns about a participant’s wellbeing directly to her GP 
 
Prior to the two year follow-up time point, a subset of eligible participants will be randomised 
in a nested study. Those in the intervention group of the sub-study will receive a combined 
pre-notification and newsletter approximately six weeks before the follow-up questionnaire is 
due. Controls will receive their follow-up questionnaire without a pre- notification mailing. If 
pre-notification is shown to significantly increase initial response  rate, consideration will be 
given to introducing it as a routine measure prior to  the remaining follow-up time points. 
Please see Appendix 1 for further details. Participants eligible for the final questionnaire 
mailing (five year time point) will be randomised in an additional nested study. The nested 
intervention group participants will receive a pen enclosed in their mailing in order to test 
whether this increases questionnaire response rates.  Please see Appendix 2 for further 
details. 
 
It is planned to enter data onto the database using a secure web-based system. This system 
will incorporate safeguards that will enable each participating site to access their own trial 
data and participant identifiers, while allowing sharing of anonymised trial data across 
participating sites. Data will be archived at the University of East Anglia and, after the primary 
analyses have been carried out, will be available upon request for secondary analyses. 
 
4.1 Invitation and baseline data collection 
 
At the time of the letter of invitation, potential study subjects will be requested to complete 
and return a consent form and a demographic questionnaire. Baseline questionnaires will be 
sent to all subjects returning a valid consent form. These will consist of a fracture risk 
assessment questionnaire, modified SF-12, the EQ-5D (excluding the visual analogue scale), 
and State-Trait Anxiety Index. 
 
4.2 Efficacy outcome measures 
 
The following efficacy outcomes will be captured: 
 
Primary outcome: 
 
• All osteoporosis-related fractures (ie. excluding those of hands, feet, nose and skull). 
 
Secondary outcomes: 
 
• All clinical fractures (ie. including hands, feet, nose and skull) 
• Hip fractures 
• Quality of life measures 
• Psychological anxiety 
• Mortality 
 
Self reported data will consist of the following: 
 
• Demographic details at invitation 
• Fracture risk questionnaire at baseline 
• EQ-5D at baseline and follow-up 
• SF-12 at baseline and follow-up 
• State-Trait Anxiety Index at baseline and follow-up 
• Fracture questionnaire at follow-up 
• Osteoporosis Medications Questionnaire at follow-up 
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The primary endpoint (all fractures with the exception of those identified above) will be 
ascertained by combining a range of data sources. At follow-up time points, study subjects 
will receive a questionnaire requesting details of any fractures during the previous follow-up 
period, including site of fracture and hospital attendance. Objective fracture information will 
be obtained via radiology information systems in hospitals serving the study sites and by 
matching study participants with hospital event records at yearly intervals. NHS number will 
be key information in this process and will be obtained at the outset for all randomised 
subjects. By using multiple sources of fracture reporting and confirmation, it will be possible 
to achieve near complete capture of events. Experience from the large MRC Hip Fracture 
Study [42] conducted in Sheffield demonstrates using similar approaches that capture of 
fractures was 100% for hip fracture and between 97% and 98% for other fractures. 
 
Quality of life will be assessed using the self-completed EQ-5D and SF-12 questionnaires. 
Psychological anxiety will be assessed using the State-Trait Anxiety Index, again self- 
completed. Anxiety over screening will also be explored using qualitative methods (see 
below). 
 
Further data will be collected at the DXA scan visit. Height and weight will be recorded. A 
variety of standard hip BMD measures (t-scores, z-score, bone mineral content), plus 
morphological measures for secondary analyses of predictors of fracture will be captured from 
the DXA scan. At some centres, where facilities exist, muscle-strength data will be taken 
again to be used for secondary analyses of predictors of fracture. Study subjects will be 
notified in advance of what the DXA scan will entail. 
 
Prescription information will be captured directly from GP records, starting approximately 5 
months after randomisation (ie. approximately 2 months post-treatment recommendation for 
high risk subjects). Treatment adherence will be captured at follow-up, where appropriate, 
using the Osteoporosis Medication Questionnaire developed at UEA from the Moriskey and 
Case index questionnaires. 
 
Mortality will be ascertained by flagging all randomized subjects via the Office of National 
Statistics. 
 
4.3 Efficacy data analysis 
 
Cox’s proportional hazards model will be used to estimate the ratio in hazard between the 
two groups for fracture (and mortality) together with a 95% confidence interval. Age and 
study centre will also be included in the model since randomization will be stratified by these 
variables. Any baseline disparities will also be included. 
 
The analysis of quality of life data will be by a general linear model with age and study centre 
as factors, and baseline value as a covariate. Again, any baseline disparities will also be 
included. 
 
Analyses will be on an intention-to-treat basis. Additionally, a subgroup analysis of those 
actually screened as intended (including DXA scan where necessary) versus control group will 
be carried out to assess the efficacy of screening (as opposed to its effectiveness). 
 
The data analysis will be the responsibility of Dr Lee Shepstone. 
 
4.4 Qualitative Data Collection and analysis 
 
Two valuable qualitative studies are considered intrinsic to the clinical trial. The first will 
provide understanding of the acceptability of the community based screening process to both 
women and GPs, which will be essential when considering the role of screening in practice. 
The second will collect information on treatment adherence, a factor important for the success 
of any screening program. Study subjects will not be invited to take part in either of these 
studies if, at consent, they indicate that they do not wish to be approached 
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regarding additional studies. Further, no subject will  be asked to take part in more than  one 
qualitative study. 
 
 
Acceptability of screening 
The first qualitative study will look at the acceptability of screening to both women and GPs. 
The study will explore how women experience different dimensions of the screening process 
that includes risk assessment, potential DXA scanning, and potential opportunities  to discuss 
the results with a GP and receive preventative treatment. As part of this, the study will explore 
the psychological reaction to, and possible anxiety created by the screening process. This 
study will also need investigate GPs’ views of the screening process, how they feel about 
discussing results with women and making decisions about treatment options for women 
identified as high risk. 
 
This qualitative study will take place in Bristol and Norwich. At each site, a purposeful sample 
of trial participants will be selected, to include those in the high and low risk groups, from 
different general practices and socio-economic backgrounds, following a maximum variation 
sampling strategy. Inclusion of both high and low risk women is important as it  will allow 
exploration of both sides of screening. Twenty women from Bristol and 10 from Norwich will 
be included. A small number of women from the usual care arm will also be interviewed to 
explore whether being invited to take part in a trial of screening for osteoporosis has an 
impact on their views of their risk and provokes any anxiety. 
 
Purposeful sampling will also be used to identify a range of GPs from practices participating 
in SCOOP, across the two qualitative study sites (Bristol and Norwich). The aim will be to 
include up to 20 GPs who have experienced the SCOOP intervention, for example by 
discussing DXA results and treatment options with women identified as at high risk of future 
osteoporotic fracture. We will aim to include GPs from practices with higher and lower 
proportions of women who have been identified as at high risk. 
 
Interviews with women will occur shortly after DXA scanning and will be conducted in their 
homes, if acceptable. The interviews with GPs will take place at the surgery, or over the 
telephone, at their preference. Topic guides will be used to ensure the primary issues are 
covered in each set of interviews, whilst allowing flexibility for new issues to emerge. 
Interviews will be recorded using a digital voice recorder, transcribed and anonymised. 
 
Data collection and analysis for each group of participants (women and GPs) will run in 
parallel. Within each group of participants, preliminary analysis of data from earlier interviews 
will shape the topics covered in later interviews. The process of data analysis for both datasets 
will be broadly similar but the two datasets will be dealt with separately, at least in the first 
instance. The software ‘ATLASti’ will be used to aid the coding, management and analysis of 
the data. 
 
Transcripts for the women or the GPs will be studied in detail, beginning with a line-by-line 
coding of the data, from which an initial coding framework will be developed. This coding 
scheme will be added to or refined and coded material regrouped as new data are collected. 
Codes will gradually be built into broader categories and themes. Analysis will draw upon the 
constant comparative method in which elements of data are continually compared to generate 
core categories and themes, and earlier analysis shapes later data collection in an iterative 
process. The data will be scrutinised for confirming and disconfirming views within themes, 
attention being given to ‘deviant’ (minority) as well as majority views. Interpretive summaries 
of the key themes will be produced, with illustrative quotes of the full range of views 
expressed by participants. 
 
At a later stage, the datasets from the women and the GPs will be compared for common and 
divergent perspectives regarding key issues, such as their experiences of discussing the 
screening results and treatment options within a consultation. 
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The qualitative research associate will meet regularly with the academic lead for the 
qualitative study (Alison Heawood) to discuss the developing coding framework. The research 
team for the qualitative study will meet regularly to discuss progress and analysis, and agree 
emerging themes. 
 
Adherence to treatment (This sub-study to be known as ‘ATOM’ – Adherence To Osteoporosis 
Medicines) 
 
A second qualitative study will be conducted seeking to ascertain the perceived factors that 
influence older women to adhere to prescribed medication to reduce fracture risk. Potential 
participants will be purposively sampled from participating high-risk subjects at the Norwich 
study site, focussing on those patients where initial follow-up data suggest they are (i) not 
using medication as planned, (ii) those prescribed an alternative treatment after a period on 
bisphosphonates, or (iii) adherent. 
 
At 6 months post-randomisation, approximately 150 participants will be sent information 
about the study by post and invited to take part with the aim of recruiting 50 subjects. This 
mailing will contain a consent form, plus a baseline questionnaire to assess cognitive / 
emotional factors relevant to medication adherence. Women who return a completed consent 
form and baseline questionnaire will be contacted by phone to arrange a home visit to conduct 
an interview about issues related to adherence. An alternative venue for the interview (eg. 
the Clinical Research and Trials Unit at UEA) will be offered if participants prefer not to be 
visited at home. 
 
These interviews will aim to cover topics such as understanding of osteoporosis, purpose of 
medication, current medication usage and any difficulties, main motivators (e.g. risk 
perception) and detractors for adherence (e.g. lack of immediate evidence of benefit). 
Relationships with health professionals and views on dosing regimens and formulations and 
other relevant views including “medicalisation” of later life will be explored. Participants will 
be asked if they agree to be followed up in approximately 2 years time. 
 
At 2 years follow-up participants will be contacted and a second home-based interview 
arranged if they are willing to take part. These interviews will cover longer term adherence 
and factors affecting persistence with treatment. 
 
4.5 Economic Analysis 
 
The determination of cost-effectiveness of the intervention is of central importance. An 
appropriately designed osteoporosis screening programme might reduce costs of fracture but 
at the same time it will incur additional costs of detection and treatment. 
 
The analysis will be undertaken from a payer’s perspective with a focus upon the direct  costs 
to the NHS, since the majority of costs of fractures fall on the health care system. The 
collected direct cost data will be as realistic as possible, reflecting current practice. For the 
screening arm this will include information regarding visits to the general practitioner, DXA 
scans, subsequent treatment, fractures and other hospital and health service use. Similar 
data will be collected for patients who are randomised to the control arm. Subsequent data 
collected at follow-up will include on-going treatment and visits to the GP, hospital and  other 
health services. The valuation of these items will be by reference to standard national price 
tariffs, unless more accurate costings are available locally. Following accepted economic 
practice in the public sector, costs and benefits that occur beyond the first year of screening 
will be discounted using a social discount rate to derive their present value (PV). A sensitivity 
analysis will be conducted to determine the impact of various discount rates and cost 
assumptions on the cost-effectiveness ratio. 
 
Since fracture can reduce the quality as well as quantity of life, a cost-utility analysis will also 
be performed. This involves estimating the cost associated with any between – group 
difference in the mean number of Quality-Adjusted Life-Years (QALYs) experienced per 
patient. The EQ-5D will be used to derive QALYs in combination with survival data. This global 
utility measure will be used for our primary cost-utility analysis.  In addition, we will 
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also use the SF12 data via the SF-6D algorithm to calculate utility values as a sensitivity 
analysis to our main EQ-5D based cost utility analysis. 
 
 
5. Trial Management 
5.1 Sponsorship 
The University of East Anglia will act as sponsor for the main SCOOP study. 
Susan Steel 
Research & Business Services, 
University of East Anglia, Norwich, 
NR4 7TJ 
 
The University of East Anglia and NHS Norfolk (primary care trust) will act as co- 
sponsors for the ATOM sub-study 
 
Dr Tracy Shalom, Research and Development Manager 
NHS Norfolk, Broadland Business Park 
Thorpe St Andrew, Norwich, NR7 OWG 
 
5.2 Funding 
 
Research funding has been secured for the main SCOOP study from the Medical Research 
Council and from the Arthritis Research Campaign. The study has also been endorsed by  the 
National Osteoporosis Society, without financial commitment. 
 
There are cost implications for the NHS from several sources, including the cost of treatment, 
GPs’ time, DXA scans and patient transport. Agreement has been secured from the 
Department of Health that these costs will be covered from Subvention funding (for treatment 
costs and GP consultations) and Service Support costs (for identification  of eligible subjects 
by GPs, DXAs and patient transport). From 2008/09 service support costs will be met via the 
UKCRN Clinical Research Network Portfolio. The cost of identifying eligible subjects in the first 
phase of participant recruitment during 2007/08 will be met through transitional funding 
arrangements. 
 
Research funding has been secured for the ATOM sub-study from the NIHR Research for 
Patient Benefit Programme (from 01.01.09). 
 
5.3 Trial Steering Committee 
 
The following have been confirmed by the MRC as Trial Steering Committee members 
 
Elaine Hay Professor of Community Rheumatology (Independent member & Chair) 
Caroline Dore arc representative 
John Kanis WHO Collaborating Centre for Metabolic Bone Diseases (Observer) 
Richard Keen Consultant Rheumatologist (Independent member) 
Elizabeth Lenaghan Trial manager 
Eugene McCloskey Lead clinician & Sheffield Principal Investigator 
Mark Pitman MRC representative 
Claire Bowring National Osteoporosis Society (Observer) 
David Scott Professor of Clinical Rheumatology (Independent member) 
Lee Shepstone Chief investigator 
Martin Underwood Professor of general practice & primary care (Independent member) 
 
This committee will meet initially on a 6-monthly basis and then annually once recruitment 
has finished. 
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5.4 Data Monitoring Committee 
 
Vern Farewell Chair 
Marwan Bukhari        Independent clinician 
Dipak Roy Independent clinician 
 
5.5 Recruiting Centres 
 
Seven centres (Norwich, Sheffield, Southampton, York, Birmingham, Manchester and Bristol) 
will be recruiting to the trial. Each centre will utilise one or more primary care trusts for 
recruitment. 
 
5.6 Day to day management of the trial 
 
Co-ordination between sites will be the responsibility of the chief investigator (Lee Shepstone) 
and the trial manager (Elizabeth Lenaghan). The will involve travel to study  sites by the 
latter on a regular basis. A research associate and a clerical post will carry out the day to day 
activities involved in running the trial at each site. In Norwich these duties will be undertaken 
by Jeanette Blacklock (local trial co-ordinator) and Veronica Bion (project administrator). 
 
A local trial management group will be formed at each site and will hold meetings on a regular 
basis. 
 
5.7 Responsibilities of the applicants 
 
Lee Shepstone will act as the Chief Investigator with overall responsibility for the trial and 
will also act as the trial statistician and the Principal Investigator for the Norwich site. There 
will be a Principal Investigator responsible for the local running of the trial at each of the other 
six sites (Eugene McCloskey, Cyrus Cooper, David Torgerson, Tim Peters & Alison Heawood 
(Co-PIs), Terence O’Neill and Neil Gittoes) together with methodological input to the trial. In 
addition, Eugene McCloskey will be the lead clinician for the study. John Kanis will provide 
methodological advice regarding the screening procedure. Alison Heawood will provide the 
academic lead for the qualitative aspect of the study investigating participants’ reactions to 
screening. Amanda Howe will be the lead primary care academic and lead the qualitative 
adherence study in conjunction with Charlotte Salter. Ric Fordham will be responsible for 
leading the economic evaluation. Tarnya Marshall will be the lead rheumatologist for the 
Norwich site. Richard Holland will provide further clinical trials advice and be the lead public 
health specialist. 
 
Randomisation will be administered locally by the site research associates using a secure 
web-based central randomisation procedure. Data will be entered locally using manual and 
automatic data entry (as used in the feasibility study) and added to the central database 
housed at Norwich, again using a web-based system. 
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Figure 1: Study Timeline 
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Trial Manager (101 months) 
Project RA (93 months  0.6 FTE) 
Project Administrator   (93 months 0.5 FTE,  8 months 0.2 FTE) 
 
 
Qualitative. RA   (18 months) 
Site RA   (24 months 1 FTE,  60 months  0.2 FTE) 
Site Secretary   (84 months 0.5 FTE) 
 
Economics RA  (12 months 1FTE) 
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Figure 2 : Main events within recruitment phases 
 
Time† Activity Study Subjects 
 
-4 Invitation mailing for trial All eligible 
 
-3½ Reminder Letter Non-responders after 18 
days 
 
-2 Baseline mailing All consenting 
 
0 Randomisation All consenting with 
baseline data 
 
+½ GP/Subject Letter advising 
study group and risk level 
Control group & 
Low risk group 
 
+1 to +4 DXA Scans High risk group 
 
+1 to +4 GP/Subject Letter advising 
treatment group 
 
+1½ to +4½ Invitation mailing for 
anxiety qualitative study 
 
+5 Start medication data 
collection 
 
+6 Medication phone call / 
mailing 
High risk group 
 
High risk group available 
for additional studies 
 
All randomised 
High risk group 
+6 Follow-Up Mailing All randomised 
 
+6  Invitation mailing for 
adherence qualitative study 
High risk group available 
for additional studies 
 
 
† Approximate time in months relative to randomisation 
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Figure 3 : Data Collection Schedule 
 
 
Invitation Baseline  DXA 
Scan Visit 
6 Month 
Follow-Up 
Annual 
Follow-Up 
 
 
 
 
Consent/Decline form ✓
Demographic questionnaire ✓
Risk factor questionnaire ✓
SF-12 questionnaire 
EQ-5D questionnaire 
State-Trait Anxiety Index 
 
 
Hip BMD for DXA group 
Height and Weight 
 
OM questionnaire 
Fracture questionnaire 
Objective incident fracture 
quest via HES data etc. 
 
 
✓ ✓ ✓
✓ ✓ ✓
✓ ✓ ✓
✓
✓
  
 
✓
✓
✓
✓
✓
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Figure 4 : Summary of study activities and documentation 
 
Activity Documentation 
 
 
 
 
 
 
 
 
   
 
 
 
 
Screening 
Group 
Controls 
GP/Practice Recruitment 
GP Information leaflet 
Participation Agreement 
Patient Letter of invitation 
Letter, patient 
information sheet, 
consent form, decline 
form, background 
information questionnaire 
Fracture Risk 
Assessment 
Letter to all subjects 
& GPs 
BMD if 
necessary 
Letter to DXA 
group subjects 
Advise 
management 
GP 
Management 
Phone call / letter 
reinforcing advice to 
high risk subjects 
Baseline Mailing Baseline questionnaire 
(self-reported risk 
factors, modified SF-12, 
EQ-5D, State-Trait 
Index) Randomisation 
Follow-Up Mailing 
Ascertain current 
therapy, Incident 
fractures 
questionnaire 
Follow-up 
questionnaire (Self-
reported fractures, SF-
12, EQ-5D, 
State-Trait Index, OMQ) 
Letter of advice to 
screening subjects 
& GPs 
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APPENDIX 1 – Protocol addendum (added 01/10/09) 
 
SCOOP sub-study: A nested randomised controlled trial of 
combined pre-contact and newsletter for increasing 
questionnaire response rates in SCOOP trial participants. 
 
1. Background 
Postal questionnaires are widely used in health research and poor response rates can 
introduce non-response bias and reduce statistical power [1, 2]. Studies in the elderly 
population have been shown to achieve a response rate of 60% or less [3, 4]. Therefore, 
methods which can be implemented to improve response rates are highly relevant to  health 
research. There have been two large reviews [5, 6] of improving response rates, both of 
these have identified pre-contact as a method for increasing response rates to 
questionnaires. Methods of pre-contact in previous studies have included contact by either 
a letter, postcard or telephone call to the participant. A Cochrane review [5] carried out a 
meta-analysis of 39 pre-contact studies, and found if participants were pre-notified the odds 
of response were increased by half. McColl et al. [6] examined pre-contact and mode of 
contact in a recent HTA report and similarly found strong evidence of the benefit of pre- 
contact. Although there have been a number of studies examining the benefit of pre- contact 
very few of these are specifically in health and there are currently no studies examining 
response rate and participant newsletter. 
 
2. Objective & method 
Currently, in the SCOOP Study there is no contact between the study centre and the 
participant during the period between questionnaire follow-ups. The purpose of this sub- 
study is to randomly allocate participants to receive a combined pre-notification and 
participant newsletter to evaluate if this will increase response rates to the SCOOP 2 year 
follow-up questionnaire (due to start in 2010). By providing participants with a newsletter 
the SCOOP Study team will be able to remind participants they are participating in the study, 
why their participation is important, and that they will soon be receiving a questionnaire. It 
also provides an opportunity to inform participants about the progress of the study across 
the country and locally. 
 
Participants in the study will be randomly assigned to either receive a newsletter or no 
newsletter. We would aim to send participants the newsletter approximately 6 weeks before 
their 2 year follow-up questionnaire is due. We propose to include participants who were 
randomised in 2008; this method allows us to capture the majority of participants  and allows 
sufficient time for analysis and a decision regarding whether participants are routinely sent 
a newsletter prior to their questionnaire if the method is shown to improve response rates.  
We anticipate our sample size will be  approximately 1,600 participants.  As this is a ‘sub-
study’ nested in a larger RCT of osteoporosis screening, our sample size 
SCOOP protocol v2.4 31Jan13.doc Page 25 of 28  
has been constrained by the number of participants recruited to the study. However, we 
anticipate sending out approximately 1,600 questionnaires which would give us 
approximately 60% power to detect an absolute difference of 5% (2p = 0.05) between the 
two groups, using a baseline of 70%. 
 
3. Outcome 
If the combined pre-notification and newsletter intervention significantly increases the initial 
response rate at the 2 year follow-up time point, consideration will be given to introducing 
it as a routine measure prior to the remaining questionnaire follow-up time points. 
 
4. References 
1. Smeeth L, Fletcher AE. Improving the response rates to questionnaires. BMJ. 
2002;324:1168-9. 
2. Taylor KSM, Counsell CE, Harris CE, Gordon JC, Fonseca SCC, Lee AJ. In a randomized 
study of envelope and ink colour, coloured ink was found to increase the response rate to a 
postal questionnaire. J Clin Epidemio. 2006;59:1326-30. 
3. Hardie JA, Bakke PS, Mørkve O. Non-response bias in a postal questionnaire survey 
on respiratory health in the old and very old. Scand J Public Health. 2003;31:411-7. 
4. Paganini-Hill A, Hsu G, Chao A, Ross RK. Comparison of early and late respondents 
to a postal health survey questionnaire. Epidemiology. 1993;4:375-9. 
5. Edwards PJ, Roberts IG, Clarke MJ, DiGuiseppi C, Wentz R, Kwan I, et al. Methods to 
increase response rates to postal questionnaires. Cochrane Database of Syst Rev: Cochrane 
Database of Syst Rev; 2007. 
6. McColl E, Jacoby A, Thomas L, Soutter J, Bamford C, Steen N, et al. Design and use 
of questionnaires: A review of best practice applicable to surveys of health service staff and 
patients. Health Technology Assessment. 2001;5(31). 
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APPENDIX 2 – Protocol addendum (added 31/01/13) 
 
A randomised controlled trial of including a pen with a follow-up questionnaire for 
increasing questionnaire response rates in older women. 
 
 
1. Background 
Postal questionnaires are a useful tool in health research and are frequently employed. If 
there is a poor response to these questionnaires a non-response bias can be introduced  and 
statistical power is reduced, therefore leading to potentially poor quality results from which 
conclusions cannot be drawn [1, 2]. 
 
Previous studies within an elderly population have yielded a response rate of  60% or less 
[3] so strategies to increase response rate are important. These studies have also shown 
that there are differences between the characteristics and outcomes of non-responders and 
responders [4-7] thus methods to increase response rates are both pertinent and necessary. 
 
One such method to increase response rate that has been identified is to include a pen with 
the questionnaire. There are mixed results regarding the effectiveness of such an 
intervention. White et al [8] found that including a study-logo pen or pencil to non- 
responders in a second mailing was a cost effective way of increasing response rates. 
Similarly Sharp et al [9] have shown that enclosing a pen with questionnaires significantly 
increases the response rate from 61.5-68.5% (P=0.002) in their patient population. 
 
Conversely studies by Clark et al and Stange et al [10, 11] have shown no significant 
difference. However these studies were performed on medical consultants and ‘recent college 
graduates’. Similarly a systematic review [12] assessing different methods to increase 
response rate to questionnaires found no significant difference when a pen was included with 
the questionnaire. Again, this trial targeted clinicians and not a patient population. 
 
When reviewing the literature it can be seen that there are few large scale studies which 
have been carried out within a patient population. More trials are necessary to assess 
whether including a pen with questionnaires affects the response rate and thus attrition in a 
healthcare trial. 
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2. Objectives 
The primary aim of this trial is to compare the effect of receiving a pen with the study logo 
with the standard first follow-up questionnaire sent on response rates to postal 
questionnaires. 
 
The secondary aims of this study are to assess whether receiving a pen with the study logo 
has an effect on: the number of reminders sent, the completeness of the primary outcome 
and the time to return the questionnaire to the study centre. 
 
3. Trial Design 
3.1 Increasing response rates 
The trial design is a two-armed pragmatic randomised controlled trial. All women that remain 
consented to receive a hard copy of the SCOOP 5 year follow-up questionnaire in 2013 will 
be included in this sub-study. A computer randomisation package will be used to randomise 
all eligible participants to either receive a pen with the SCOOP study logo on with their 60-
month questionnaire or receive their 60-month questionnaire alone. Study logo pens will be 
included with the original 60 month follow-up questionnaire; where a reminder questionnaire 
is necessary a study logo pen will not be included with this reminder mailing. We anticipate 
our sample size will  be approximately 8000 participants. As this is a ‘sub-study’ nested in a 
larger RCT of osteoporosis screening, the sample size has been constrained by the number 
of participants recruited to the study and have consented to receive follow-up by paper 
questionnaire. However, we anticipate sending out approximately 4000 pens which would 
give us approximately 60% power to detect an absolute difference of 5% (2p = 0.05) 
between the two groups, using a baseline of 90%. 
 
4. Statistics 
 
All analyses will be conducted in Stata using two-sided significance testing at the 5% 
significance level on an intention to treat basis. 
 
The primary outcome is the overall questionnaire response rate (number of patients who 
returned the follow up questionnaire divided by the number that did not for the  intervention 
and control groups). 
 
The secondary outcomes are: number of reminders sent (number of participants requiring a 
reminder mailing divided by the number of participants sent a questionnaire), completeness 
of the primary outcome (number of participants with a complete primary outcome divided 
by the number of patients returning a questionnaire) and time to  response (the time to 
return the questionnaire to the study centre). 
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Univariate odds ratios (ORs) will be calculated for each response rate and the log rank test 
shall be used to compare the time to response between the intervention and control groups. 
 
5. Ethics 
Ethical approval will be necessary for this sub-study as participants randomised to  receiving 
a SCOOP study logo pen will be receiving an additional item with their questionnaire. 
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